All In Biotech

Drug Trial Radar · NCT00521950

Cost-effectiveness of TPMT Pharmacogenetics

Pharmacogenetic Testing in the Clinical Setting: is Screening for TPMT Genotype a Cost-effective Treatment Strategy? - The First Prospective Randomized Controlled Trial Within the Dutch Health Care System.

Last checked: Nov 20, 2026Latest source record: Mar 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 853 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

853

Actual

Start

Sep 2007

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Radboud University Medical Center
First posted
Aug 28, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether thiopurine S-methyltransferase (TPMT) genotyping prior to thiopurine use is cost-effective in patients with inflammatory bowel disease (IBD) in need of immune suppression. The study is designed to test the hypothesis that optimization of initial thiopurine dose based on pre-treatment TPMT genotyping will maximize treatment efficacy and minimize adverse drug reactions (ADRs) resulting in reduced costs.

Conditions

  • Inflammatory Bowel Diseases
  • Crohn Disease
  • Ulcerative Colitis

Interventions

  • TPMT genotyping; Drug: azathioprine or 6-mercaptopurineGenetic

    Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT\*2, \*3A, \*3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity. Patients are advised an initial treatment dose based on the enzyme activity: * Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care); * Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day; * Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;

  • azathioprine (AZA) or 6-mercaptopurine (6-MP)Drug

    Patients will be advised a standard initial treatment dose: * AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Haematological adverse drug reactionsTime frame: 0-5 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Bernhoven Hospital

    Oss, Netherlands

  • Bernhoven Hospital

    Veghel, Netherlands

  • Radboud University Medical Center

    Nijmegen, Gelderland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.